Sa, Jason K.
Hwang, Jae Ryoung
Cho, Young-Jae
Ryu, Ji-Yoon
Choi, Jung-Joo
Jeong, Soo Young
Kim, Jihye
Kim, Myeong Seon
Paik, E. Sun
Lee, Yoo-Young
Choi, Chel Hun
Kim, Tae-Joong
Kim, Byoung-Gie
Bae, Duk-Soo
Lee, Yeri
Her, Nam-Gu
Shin, Yong Jae
Cho, Hee Jin
Kim, Ja Yeon
Seo, Yun Jee
Koo, Harim
Oh, Jeong-Woo
Lee, Taebum
Kim, Hyun-Soo
Song, Sang Yong
Bae, Joon Seol
Park, Woong-Yang
Han, Hee Dong
Ahn, Hyung Jun
Sood, Anil K.
Rabadan, Raul
Lee, Jin-Ku http://orcid.org/0000-0003-0263-3234
Nam, Do-Hyun
Lee, Jeong-Won
Funding for this research was provided by:
Korea National Institute of Health (HI14C3418)
Article History
Received: 9 April 2019
Accepted: 2 October 2019
First Online: 26 November 2019
Ethics approval and consent to participate
: The study was approved by the local committee on the use of human samples for experimental studies of the Samsung Medical Center (SMC), Seoul, Republic of Korea (IRB file #201004004). Written informed consents were provided by the participants prior to enrollment. All experimental methods abided by the Helsinki Declaration.
: Not applicable
: Do-Hyun Nam is the CEO of AimedBio Inc. and owns shares of AimedBio Inc. which owns IPs for Avatascan. The other authors declare that they have no competing interests.